04 March 2022>: Articles
Dramatic Response to Trastuzumab Deruxtecan Rechallenge in a Patient with HER2-Positive Gastric Cancer: A Case Report
Unusual setting of medical care
Takatsugu Ogata A , Yasuko Fujita B , Kei Muro A*DOI: 10.12659/AJCR.935600
Am J Case Rep 2022; 23:e935600
Table 2. Laboratory data on the administration of T-DXd.
Hematology | Normal range | |
---|---|---|
White blood cell | 13060/μL | 3300–8600 |
Neutrophil | 79.0% | |
Eosinophil | 3.5% | |
Basophil | 0.0% | |
Monophil | 9.0% | |
Lymphocyte | 8.5% | |
Red blood cell | 451×10/μL | 386–492×10 |
Hemoglobin | 9.4 g/dL | 11.6–14.8 |
Platelet | 38.3×10/μL | 15.8–34.8×10 |
ALT – alanine aminotransferase; AST – aspartate aminotransferase; BUN – blood urea nitrogen; Ca – calcium; CA19-9 – carbohydrate antigen 19-9; CA125 – cancer antigen 125; CEA – carcinoembryonic antigen; CRP – C-reactive protein; K – potassium; LDH – lactate dehydrogenase; Na – sodium; T-DXd – trastuzumab deruxtecan. | ||
Tumor marker | Normal range | |
CEA | 2.3 ng/mL | |
CA19-9 | 42.2 U/mL | |
CA125 | 61.0 U/mL | |
ALT – alanine aminotransferase; AST – aspartate aminotransferase; BUN – blood urea nitrogen; Ca – calcium; CA19-9 – carbohydrate antigen 19-9; CA125 – cancer antigen 125; CEA – carcinoembryonic antigen; CRP – C-reactive protein; K – potassium; LDH – lactate dehydrogenase; Na – sodium; T-DXd – trastuzumab deruxtecan. | ||
Biochemistry | Normal range | |
Total protein | 6.0 g/dL | 6.7–8.3 |
Albumin | 3.3 g/dL | 4.0–5.0 |
Total bilirubin | 0.5 mg/dL | 0.3–1.2 |
AST | 10 U/L | 13–33 |
ALT | 6 U/L | 6–27 |
LDH | 156 U/L | 119–229 |
BUN | 16.7 mg/dL | 8–22 |
Creatinine | 1.00 mg/dL | 0.40–0.70 |
Na | 138 mmol/L | 138–146 |
K | 3.7 mmol/L | 3.6–4.9 |
Ca | 8.2 mg/dL | 8.7–10.3 |
CRP | 4.23 mg/dL | |
ALT – alanine aminotransferase; AST – aspartate aminotransferase; BUN – blood urea nitrogen; Ca – calcium; CA19-9 – carbohydrate antigen 19-9; CA125 – cancer antigen 125; CEA – carcinoembryonic antigen; CRP – C-reactive protein; K – potassium; LDH – lactate dehydrogenase; Na – sodium; T-DXd – trastuzumab deruxtecan. |